跳至主要内容
临床试验/NCT00044421
NCT00044421已完成3 期

LY333531 Treatment of Peripheral Neuropathy in Patients With Diabetes

Eli Lilly and Company70 个研究点 分布在 10 个国家目标入组 400 人开始时间: 2002年7月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
400
试验地点
70
主要终点
Reduction in the progression of DPN measured by composite score

研究概览

简要总结

The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must have type I or type II Diabetes Mellitus.
  • Have been clinically diagnosed with neuropathy.
  • Have an HbA1C less than or equal to 12%. Patients with HbA1C greater than 9% must be on insulin therapy.
  • Must be 18 years or older.
  • Be able to visit the doctor's office approximately 3 times over a maximum of a 6-week period to determine if you can continue in the study.

排除标准

  • History of significant liver problems.
  • Have poor kidney function.
  • Drink an excess of alcohol or abuse drugs.
  • Have recently participated in or are currently participating in a Medical study in which you receive an experimental drug.
  • Are a woman and are pregnant or breastfeeding, intending to become pregnant within the next 2 years, or are a woman not using an effective method of birth control.

结局指标

主要结局

Reduction in the progression of DPN measured by composite score

次要结局

  • Vibration sensation;Electrophysiology of tibial, peroneal and sural nerves;Neurological signs;Neuropathic symptoms;Clinical global impression of change;Health outcome measures

研究者

申办方类型
Industry

研究点 (70)

Loading locations...

相似试验